Silexion Therapeutics Corp Ordinary Shares (SLXN)

FairStock Score: 31/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At the close on 2026-10-13, Silexion traded at $0.18, giving a $4.0M market value. In the filed figures, revenue is n/a for FY2023, FY2024, FY2025, fiscal Q1 2026, and fiscal Q2 2026. Net losses were $5.1M in FY2023, $16.5M in FY2024, and $11.9M in FY2025; in fiscal Q2 2026 (quarter ended 2026-06-30) the company lost another $3.6M. Trailing free cash flow is -$12.4M, and the FairStock FCF yield is -313.7%, meaning the business consumes cash at a rate far larger than its market value. The FairStock ratios show D/E 32.05, P/B 17.60, ROE -897.46%, ROCE -123.27%, Piotroski 1/9, and Altman Z-Score -19.76. The Lynch category is none because it lost money in each of the last three years. This is a 13-employee clinical-stage biotech developing RNAi cancer drugs and the LODER delivery platform. The science may be interesting, but I see no commercial product, no revenue, and no durable moat yet. A Graham-style investor wants a margin of safety; here the market cap is tiny, the cash burn is heavy, and book value is already 17.6 times the price by FairStock's calculation. The company depends on trial results, partnerships, and outside financing. Until those arrive, the growth trajectory is essentially a race between scientific progress and cash depletion. The shares may be cheap in absolute dollars, but not on the fundamentals shown.

In plain English: Silexion Therapeutics is a tiny drug company trying to make RNA-based cancer treatments. It has no reported revenue and has lost money for years, so the business looks financially weak. At 18 cents a share, the price does not look cheap compared with its losses and weak financial position, although it is a very small early-stage company.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer